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ETTERS TO THE EDITOR
OPD: Evidence-based failure.  Others  suggest  a  mild  level,  requiring  no  change
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OPD  is  the  most  common  chronic  respiratory  disease.  Today
t  is  the  4th  highest  cause  of  death  worldwide  and  therefore
t  should  always  be  considered  when  a  patient  has  chronic
yspnea,  cough  with  or  without  sputum  production,  and  a
istory  of  exposure  to  risk  factors.  The  diagnosis  always
equires  a  spirometry  and  the  ratio  FEV1/FVC  (or  FEV1/VC)  is
hat  is  normally  accepted  as  the  index  that  deﬁnes  airway
bstruction.1 Airﬂow  limitation  that  is  not  fully  reversible
s  deﬁned  by  the  Global  Initiative  for  Obstructive  Lung
iseases2 (GOLD)  as  a  post-bronchodilator  FEV1/FVC  <  0.7,
nd  by  the  ATS/ERS  Task  Force  position  paper3 as  a  ratio
0.7.  However,  this  diagnostic  criterion  has  been  increas-
ngly  questioned.  Although  simpler  and  easier  to  use  in
rimary  care  settings  worldwide,  some  authors  have  claimed
hat  it  can  miss  the  diagnosis  in  younger,  predominantly
emale  individuals  where  an  early  diagnosis  brings  the  great-
st  beneﬁt,  and  can  lead  to  over-diagnosis  of  COPD  in
lder  men,  missing  a  heart  disease  diagnosis,  or  even  an
sthma  diagnosis,  which  require  a  different  approach.  So,
hey  argue  that  the  lower  limit  of  normal  (LLN)  criterion
FEV1/FVC  <  LLN)  should  be  used  instead.  Some  authors  also
ropose  a  low  FEV1/FVC  ratio  in  any  criteria,  coupled  with
 FEV1  <0.8  of  the  predicted  value.4 In  fact,  there  is  cur-
ently  no  consensus  about  the  best  criteria  to  be  used  in
OPD.  In  2010,  150  international  experts  and  12  interna-
ional  organizations  asked  GOLD  to  change  its  deﬁnition  of
irﬂow  obstruction  to  LLN  criterion,5 and,  in  relation  to  the
se  of  LLN,  a  recent  editorial  in  the  ERJ  stresses  the  need
o  improve  the  diagnosis  of  early  COPD.
The  goals  of  the  treatment  are  symptomatic  improve-
ent  and  prevention  of  disease  progression  and  exacer-
ations.  The  high  mortality  of  COPD  is  mainly  due  to
xacerbations  requiring  hospitalization.  Exacerbations  are
n  COPD  what  myocardial  infarctions  are  in  coronary  artery
isease6:  acute,  disease  modifying,  causing  high  mortality
uring  hospitalization  and  in  the  ﬁrst  year  after  discharge,
nd  decreased  quality  of  life.  At  present  there  is  neither
 good  deﬁnition  nor  an  agreed  classiﬁcation  of  exacerba-
ion.  Some  authors  propose  3  levels  of  exacerbation;  home
reated,  requiring  hospitalization  and  leading  to  respiratory
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rate  level,  requiring  systemic  corticosteroids/antibiotics
nd  a  severe  level,  requiring  hospitalization.  In  addition,
he  usual  deﬁnition  of  exacerbation  as  an  event  character-
zed  by  a change  in  the  patient’s  baseline  dyspnea,  cough  or
putum  beyond  day-to-day  variability,  that  needs  a  change
n  medication,  is  difﬁcult  to  use  in  clinical  practice  and
ther  deﬁnitions  are  needed,  for  operational  reasons,  such
s  clinical  trials.
For  therapeutic  success  in  COPD  an  appropriate  ther-
py  is  essential,  combined  with  a  good  level  of  adherence
nd  correct  inhalation  technique.  Although  the  clinical  and
cientiﬁc  bases  of  some  guidelines  are  now  increasingly
ebatable,7 they  represent  a  standard  of  care,  allowing  us  to
nd  answers  in  Evidence  Based  Medicine  and  therefore  can-
ot  be  ignored.  However  there  are  numerous  other  factors8
elating  to  the  patients  themselves  or  to  the  doctor--patient
elationship,  which  determine  the  therapeutic  efﬁcacy:  the
atient  is  unaware  of  the  nature  of  COPD,9 plays  down
ymptoms  and  the  severity  of  the  disease,  and  a set  of  socio-
ultural  beliefs  or  concepts  seem  to  persist  in  relation  to
nhaled  medication,  which  can  constitute  poor  adherence
actors.
Rand  CS10 did  an  exhaustive  review  of  the  literature  with
egard  to  adherence  to  therapy  in  patients  with  COPD,  and
oncluded  that  the  clinical  evidence  on  this  topic  is  not  very
obust,  in  fact  it  seems  very  poor,  and  more  inﬂuenced  by
he  beliefs  of  patients  about  the  medicines,  than  by  disease
everity  or  demographic  factors.  Bryant  and  colleagues11
onsider  that  knowledge  about  adherence  to  treatment,  and
ts  improvement  is  critical  in  the  treatment  of  patients  with
OPD.  But  if  adherence  is  a  difﬁcult  concept  to  deﬁne,
t  is  even  more  difﬁcult  to  measure,  because  there  is  no
‘best  way’’.  As  well  as  inadequate  knowledge  about  adher-
nce,  little  is  known  regarding  the  patient’s  beliefs12 about
edicines,  in  COPD.
Therapeutic  success  is  also  dependent  on  a good  inhaler
echnique,  but  we  do  not  know  how  the  patient  uses  the
elivery  devices,  nor  is  there  a ‘‘best  method’’  for  assessing
he  inhalation  technique,  and  there  is  little  evidence  about
he  choice  of  the  optimal  delivery  method  or  device  for  each
atient.13
Thus,  in  clinical  practice,  knowing  the  best  medical
vidence,  although  mandatory,  is  currently  not  enough,  and
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we  have  to  focus  heavily  on  patient  education,  with  respect
to  illness  and  treatment,  and  participation  in  clinical
decisions,  allowing  for  patients’  perspectives,  their
medicine  and  inhalation  device  preferences,  and  also  their
disease  and  therapeutic  related  beliefs.  We  also  need  to
know  the  physical  and  emotional  needs  of  the  patients,
and  to  treat  the  comorbid  conditions,  in  order  to  achieve
a  better  control  of  COPD.  For  this  purpose,  we  emphasize
the  key  role  of  the  patient’s  family  or  caregivers,  and  the
importance  of  a  multidisciplinary  team  in  patient-centered
medicine.  More  than  the  diagnosis  and  treatment,  patient
centered  COPD  care  involves  working  with  the  patient  to
provide  the  best  care  possible  and  improvement  in  their
quality  of  life.
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Spontaneous
pneumomediastinum in
pregnancy: A case report
Dear  Editor-in-Chief,
Postpartum  spontaneous  pneumomediastinum  (Hamman’s
Syndrome)  is  a  well-known  but  rare  complication  of
pregnancy  which  is  potentially  lethal.  However,  cur-
rent  international  pneumothorax  guidelines  do  not  give
any  advice  on  the  management  of  this  life-threatening
event.1--4
We  report  the  case  of  a  30-year-old  woman  who  came  to
our  attention  at  the  40th  week  of  her  pregnancy.  She  was  a
non-smoker  and  had  no  history  of  pulmonary  diseases.
During  the  later  part  of  labor,  she  suddenly  developed
facial  edema,  subcutaneous  thoracic  emphysema  and  dys-
Blood  pressure  and  cardiac  rate  were  normal  and  senso-
rium  was  intact  (Kelly  score  =  1).
Chest  CT  scan  showed  a  large  pneumomediastinum  with
bilateral  pneumothorax  (Fig.  1).
The  patient  was  submitted  to  cardio-respiratory  monitor-
ing  and  treated  with  oxygen  and  conservative  therapy.
Within  ﬁve  days  of  hospitalization,  the  patient’s  condi-
tion  improved  with  complete  resolution  of  the  subcutaneous
emphysema  and  a  partial  reabsorption  of  both  pneumome-
diastinum  and  pneumothorax.
After  a  follow-up  of  two  weeks,  chest  X-ray  turned  out
to  be  normal.
Patho-physiologically,  the  development  of  pneumomedi-
astinum  during  spontaneous  delivery  is  linked  to  the  sudden
laceration  of  the  alveola  due  to  the  increase  of  intrathoracic
and  intra-abdominal  pressure  caused  by  repeated  Valsalva
maneuvers  (Fig.  2).
The  main  physiological  alterations  of  the  respiratory  sys-
pnea.
Arterial  blood  gas  analysis  revealed  severe  hypoxemia
and  hypocapnia.
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rem  that  occurred  during  the  last  part  of  pregnancy  are
ainly  the  consequence  of  the  progestin  stimulation  of  the
espiratory  drive  and  consist  of  a  reduction  in  the  functional
